Exact Sciences Corp
Company Profile
Business description
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
Contact
5505 Endeavor Lane
MadisonWI53719
USAT: +1 608 284-5700
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2024
Employees
6,600
Exact Sciences Corp News & Analysis
etfs
ARK Innovation ETF has likely been a disappointment for most investors
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,316.70 | 98.30 | -1.17% |
| CAC 40 | 7,274.48 | 19.89 | -0.27% |
| DAX 40 | 19,884.75 | 85.11 | -0.43% |
| Dow JONES (US) | 42,840.26 | 498.02 | 1.18% |
| FTSE 100 | 8,084.61 | 20.71 | -0.26% |
| HKSE | 19,720.70 | 31.81 | -0.16% |
| NASDAQ | 19,572.60 | 199.83 | 1.03% |
| Nikkei 225 | 38,701.90 | 111.68 | -0.29% |
| NZX 50 Index | 12,904.11 | 149.96 | 1.18% |
| S&P 500 | 5,930.85 | 63.77 | 1.09% |
| S&P/ASX 200 | 8,067.00 | 101.20 | -1.24% |
| SSE Composite Index | 3,368.07 | 1.96 | -0.06% |